141 related articles for article (PubMed ID: 28150469)
1. Targeting canine mammary tumours via gold nanoparticles functionalized with promising Co(II) and Zn(II) compounds.
Raposo LR; Roma-Rodrigues C; Jesus J; Martins LMDRS; Pombeiro AJ; Baptista PV; Fernandes AR
Vet Comp Oncol; 2017 Dec; 15(4):1537-1542. PubMed ID: 28150469
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional gold-nanoparticles: A nanovectorization tool for the targeted delivery of novel chemotherapeutic agents.
Fernandes AR; Jesus J; Martins P; Figueiredo S; Rosa D; Martins LM; Corvo ML; Carvalheiro MC; Costa PM; Baptista PV
J Control Release; 2017 Jan; 245():52-61. PubMed ID: 27871990
[TBL] [Abstract][Full Text] [Related]
3. Immortalization and characterization of a new canine mammary tumour cell line FR37-CMT.
Raposo LR; Roma-Rodrigues C; Faísca P; Alves M; Henriques J; Carvalheiro MC; Corvo ML; Baptista PV; Pombeiro AJ; Fernandes AR
Vet Comp Oncol; 2017 Sep; 15(3):952-967. PubMed ID: 27140424
[TBL] [Abstract][Full Text] [Related]
4. Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.
Bakirel T; Alkan FÜ; Üstüner O; Çinar S; Yildirim F; Erten G; Bakirel U
J Vet Med Sci; 2016 May; 78(4):657-68. PubMed ID: 26822118
[TBL] [Abstract][Full Text] [Related]
5. Characterization of protein marker expression, tumorigenicity, and doxorubicin chemoresistance in two new canine mammary tumor cell lines.
Hsiao YL; Hsieh TZ; Liou CJ; Cheng YH; Lin CT; Chang CY; Lai YS
BMC Vet Res; 2014 Sep; 10():229. PubMed ID: 25267010
[TBL] [Abstract][Full Text] [Related]
6. Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.
Zambrano-Estrada X; Landaverde-Quiroz B; Dueñas-Bocanegra AA; De Paz-Campos MA; Hernández-Alberto G; Solorio-Perusquia B; Trejo-Mandujano M; Pérez-Guerrero L; Delgado-González E; Anguiano B; Aceves C
BMC Vet Res; 2018 Mar; 14(1):87. PubMed ID: 29530037
[TBL] [Abstract][Full Text] [Related]
7. Aldoxorubicin-loaded nanofibers are cytotoxic for canine mammary carcinoma and osteosarcoma cell lines in vitro: A short communication.
Stokol T; Wan C; Blakely R; Bellat V; Law B
Res Vet Sci; 2020 Feb; 128():86-89. PubMed ID: 31760317
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.
Guillemette S; Rico C; Godin P; Boerboom D; Paquet M
J Mammary Gland Biol Neoplasia; 2017 Sep; 22(3):203-214. PubMed ID: 28822004
[TBL] [Abstract][Full Text] [Related]
9. Calotropis procera (Aiton) Dryand (Apocynaceae) as an anti-cancer agent against canine mammary tumor and osteosarcoma cells.
Rabelo AC; Borghesi J; Carreira ACO; Hayashi RG; Bessa F; Barreto RDSN; da Costa RP; Cantanhede Filho AJ; Carneiro FJC; Miglino MA
Res Vet Sci; 2021 Sep; 138():79-89. PubMed ID: 34119813
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study.
Arenas C; Peña L; Granados-Soler JL; Pérez-Alenza MD
Vet Rec; 2016 Jul; 179(5):125. PubMed ID: 27377395
[TBL] [Abstract][Full Text] [Related]
11. Significance of caveolin-1 and matrix metalloproteinase 14 gene expression in canine mammary tumours.
Ebisawa M; Iwano H; Nishikawa M; Tochigi Y; Komatsu T; Endou Y; Hirayama K; Taniyama H; Kadosawa T; Yokota H
Vet J; 2015 Nov; 206(2):191-6. PubMed ID: 26364240
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs.
Simon D; Knebel JW; Baumgartner W; Aufderheide M; Meyer-Lindenberg A; Nolte I
Am J Vet Res; 2001 Nov; 62(11):1825-30. PubMed ID: 11703031
[TBL] [Abstract][Full Text] [Related]
13. Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumour cells.
Vigneau AL; Rico C; Boerboom D; Paquet M
Vet Comp Oncol; 2022 Jun; 20(2):437-448. PubMed ID: 34881506
[TBL] [Abstract][Full Text] [Related]
14. Risk factor analysis and clinicopathological characteristics of female dogs with mammary tumours from a single-center retrospective study in Poland.
Dolka I; Czopowicz M; Stopka D; Wojtkowska A; Kaszak I; Sapierzyński R
Sci Rep; 2024 Mar; 14(1):5569. PubMed ID: 38448646
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer.
Atmane MI; Vigneau AL; Beaudry F; Rico C; Boerboom D; Paquet M
Vet Comp Oncol; 2023 Dec; 21(4):634-645. PubMed ID: 37709554
[TBL] [Abstract][Full Text] [Related]
16. Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells.
Gelaleti GB; Borin TF; Maschio-Signorini LB; Moschetta MG; Hellmén E; Viloria-Petit AM; Zuccari DAPC
Vet Comp Oncol; 2017 Dec; 15(4):1572-1584. PubMed ID: 28322030
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a HER2-enriched canine mammary cancerous myoepithelial cell line.
Chen A; Ye S; Zheng J; Li J; Chen Z; Zhang Y; Li S
BMC Vet Res; 2023 Jan; 19(1):22. PubMed ID: 36717813
[TBL] [Abstract][Full Text] [Related]
18. Effect of the VP3 gene of chicken anemia virus on canine mammary tumor cells.
Lee JJ; Chen PB; Yang SH; Cheng CH; Chueh LL; Pang VF; Hsiao M; Lin CT
Am J Vet Res; 2007 Apr; 68(4):411-22. PubMed ID: 17397298
[TBL] [Abstract][Full Text] [Related]
19. The antiprogestins mifepristone and onapristone reduce cell proliferation in the canine mammary carcinoma cell line CMT-U27.
Guil-Luna S; Hellmén E; Sánchez-Céspedes R; Millán Y; Martín de las Mulas J
Histol Histopathol; 2014 Jul; 29(7):949-55. PubMed ID: 24500783
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the KLF4 transcription factor inhibits the proliferation and migration of canine mammary tumor cells.
Tien YT; Chang MH; Chu PY; Lin CS; Liu CH; Liao AT
Vet J; 2015 Aug; 205(2):244-53. PubMed ID: 25616642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
